Jaguar Animal Health Inc
$ 0.41
4.10%
14 Apr - close price
- Market Cap 5,077,500 USD
- Current Price $ 0.41
- High / Low $ 0.42 / 0.38
- Stock P/E N/A
- Book Value -2.83
- EPS -22.97
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.62 %
- ROE -4.12 %
- 52 Week High 15.48
- 52 Week Low 0.31
About
Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California.
Analyst Target Price
$7.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-13 | 2024-05-14 | 2024-01-31 | 2023-11-14 | 2023-08-14 | 2023-05-15 | 2023-03-27 |
| Reported EPS | -6.28 | -10.26 | -18.7722 | -125.8 | -1.05 | -4.04 | -0.07 | -33 | -0.55 | -0.69 | -2.3881 | -3.4297 |
| Estimated EPS | -0.22 | -0.28 | -10.82 | -18.5 | -2.37 | -1.2 | -0.03 | -73.8 | -1.23 | -1.53 | -0.04 | -9.75 |
| Surprise | -6.06 | -9.98 | -7.9522 | -107.3 | 1.32 | -2.84 | -0.04 | 40.8 | 0.68 | 0.84 | -2.3481 | 6.3203 |
| Surprise Percentage | -2754.5455% | -3564.2857% | -73.4954% | -580% | 55.6962% | -236.6667% | -133.3333% | 55.2846% | 55.2846% | 54.902% | -5870.25% | 64.8236% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: JAGX
2026-04-13 22:40:11
Jaguar Health, Inc. announced plans to utilize AI platforms to improve the development and commercialization of crofelemer for intestinal failure treatments, particularly for pediatric microvillus inclusion disease (MVID). The company believes AI can aid in personalized patient regimens, provide real-world evidence, and accelerate drug development for diseases like MVID, which currently lack alternative treatments. Jaguar is also pursuing Breakthrough Therapy designation from the FDA for MVID and is seeking non-dilutive funding from potential partners.
2026-04-13 12:39:26
Jaguar Health, Inc. announced plans to leverage AI platforms to accelerate the development, commercialization, and healthcare delivery of crofelemer for intestinal failure, particularly for pediatric microvillus inclusion disease (MVID). The company aims to use AI to guide personalized treatment regimens, provide real-world evidence, and potentially achieve Breakthrough Therapy designation from the FDA for MVID, a rare disease with no current alternative treatments. This strategy seeks to provide more efficient drug development and faster patient access to their critical medication.
2026-04-13 12:39:26
Jaguar Health (NASDAQ:JAGX) plans to integrate AI platforms to advance the development and commercialization of crofelemer for intestinal failure (IF), including pediatric microvillus inclusion disease (MVID), a condition with no existing treatments. The company cited significant reductions in parenteral support during an investigator-sponsored MVID program and is pursuing Breakthrough Therapy designation from the FDA, while seeking non-dilutive partner funding to accelerate approval and patient access. This AI initiative aims to streamline drug development and provide real-world evidence to support crofelemer's effectiveness in this ultrarare and lethal pediatric disorder.
2026-04-11 06:39:57
Jaguar Health Inc (JAGX) reported a 5% increase in net revenue for Q4 2025 compared to Q3 2025, reaching $3.2 million, and secured a transformative US out-license agreement with Future Pak for Mytesi, providing $18 million upfront. Despite these positives, the company experienced an 8% decrease in revenue compared to Q4 2024 and significant increases in operational loss and net loss. JAGX plans to focus on rare disease intestinal failure indications and aims to file a new drug application by 2027.
2026-04-10 14:10:40
Jaguar Health (JAGX) reported a significant miss on both EPS and revenue targets for Q4 2025, with EPS at -$4.38 against a forecasted -$0.16, and revenue at $3.24 million versus an expected $8.35 million. The company's stock fell by 2.71% following the announcement, reflecting a challenging period as it shifts towards a licensing model to fund its rare disease pipeline. Executives emphasized the strategic pivot and its potential for long-term growth despite short-term revenue volatility and continued projected EPS losses into 2027.
2026-04-10 13:39:16
Jaguar Health (JAGX) reported a 5% sequential increase in Q4 2025 net revenue, despite an 8% year-over-year decline. The company is strategically shifting its focus to rare diseases and secured a $16 million upfront payment through a transformative out-license deal. Clinical milestones for crofelemer in intestinal failure are anticipated within the next 6-12 months.
